Related Experiment Video

Updated: Aug 9, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Antisense-based cancer therapeutics: are we there yet?

Elizabeth Rose Rayburn1, Hui Wang, Ruiwen Zhang

  • 1University of Alabama at Birmingham, Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, VH 113, 1670 University Blvd., Birmingham, AL 35294, USA

Expert Opinion on Emerging Drugs
|April 26, 2006
PubMed

Insights

Antisense oligonucleotides offer a promising nucleic acid-based approach for novel cancer therapies. Ongoing advancements in chemical modifications and delivery systems are overcoming challenges, positioning them for clinical use alone or with traditional treatments.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • There is a persistent need for improved, less toxic cancer therapeutics.
  • Antisense oligonucleotides represent a novel molecular therapeutic strategy.
  • Several antisense agents are in preclinical and clinical development for cancer.

Purpose of the Study:

  • To highlight the potential of antisense oligonucleotides as a cancer therapy.
  • To discuss the challenges and recent progress in developing antisense strategies for cancer.
  • To explore the role of antisense oligonucleotides in combination cancer treatment.

Main Methods:

  • Review of current research on antisense oligonucleotide development for cancer.
  • Analysis of advancements in chemical modifications, target selection, and drug delivery.
  • Evaluation of clinical trial data for anticancer antisense drugs.

Main Results:

  • Antisense oligonucleotides show promise as a nucleic acid-based cancer therapeutic approach.
  • Progress in chemical modifications, target selection, and delivery systems is addressing development challenges.
  • Antisense oligonucleotides are emerging as a viable option for monotherapy or combination therapy.

Conclusions:

  • Antisense oligonucleotides are a promising novel approach for human cancer therapy.
  • Continued progress in the field is expected to overcome existing limitations.
  • These agents can be used independently or integrated with conventional cancer treatments.

More Related Videos

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents09:18

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents

Published on: June 2, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...